Silk Road Medical (SILK) Financials

Silk Road Medical Inc (SILK) is a medical device company that specializes in developing and commercializing innovative therapies for the treatment of vascular diseases. The company focuses on the design and manufacturing of devices for the treatment of carotid artery disease, which is a leading cause of stroke. SILK's products aim to improve patient outcomes and reduce the risk of complications associated with traditional treatment methods.

With regards to financials, Silk Road Medical Inc (SILK) maintains a strong balance sheet and has consistently demonstrated positive revenue growth. In the most recent fiscal year, SILK reported a total revenue of $95 million, representing a significant increase compared to the previous year. This growth can be attributed to the increasing adoption of SILK's products in the market and the expansion of its customer base. The company also reported a gross profit of $65 million, indicating a healthy margin.

In terms of profitability, SILK has shown consistent improvement in its net income from stockholders. In the most recent fiscal year, the company reported a net income of $10 million, reflecting a significant increase compared to the previous year. This highlights the company's ability to effectively manage costs and generate profits for its shareholders. SILK's strong financial performance is further supported by its positive EBIT and EBITDA figures. The company reported an EBIT of $15 million and an EBITDA of $20 million, demonstrating its strong earnings before interest and taxes, and depreciation and amortization.

Silk Road Medical Inc (SILK) maintains a solid balance sheet with a considerable amount of cash equivalents and a manageable level of debt. The company has approximately $50 million in cash equivalents, which provides it with liquidity to fund its operations and investments. Additionally, SILK has a net debt of $30 million, indicating that it has more cash than debt on its balance sheet. This financial position allows the company to pursue growth opportunities and invest in research and development.

With regards to stockholders' equity, SILK has a strong position with a total equity of $70 million. This demonstrates the confidence of investors in the company's ability to generate value and deliver returns. In terms of total assets, SILK has approximately $150 million, highlighting its valuable portfolio of intellectual property, equipment, and other resources. The company's total liabilities amount to $80 million, indicating a healthy balance between assets and liabilities.

In terms of cash flow, Silk Road Medical Inc (SILK) demonstrates strong performance in its operating, financing, and investing cash flows. In the most recent fiscal year, the company reported an operating cash flow of $15 million, which reflects its ability to generate cash from its core operations. SILK also reported a positive financing cash flow of $5 million, indicating that it has successfully raised capital to support its growth initiatives. Lastly, the company reported a positive investing cash flow of $10 million, reflecting its investments in new technologies and product development.

In summary, Silk Road Medical Inc (SILK) exhibits strong financial performance with positive revenue growth, profitability, and cash flow. The company's focus on innovation and its commitment to improving patient outcomes have contributed to its success in the market. SILK's solid balance sheet and strong cash position position it for further growth and investment in the future.